AMI

News AMI

• Takeda Announces Top Line Results from Phase 2 Study of Investigational Compound, TAK-442 for the patients with ACS

  Top line data from a phase 2 study of TAK-442, an oral anticoagulant, biologically active factor Xa inhibitor (fXai), under investigation by Takeda, are now available. This phase 2, multi-center, randomized double blind, placebo-controlled study conducted globally except in Japan was designed to eva more

• Abbott Reports Psoriasis Phase III Results of its Investigational IL-12/23 Inhibitor Briakinumab (ABT-874)

  In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874), achieved 75 percent or better skin clearance rates than those treated with etan more

• Trophos initiates clinical development for novel cardioprotective compound, TRO40303

  Trophos SA announced the initiation of clinical development for TRO40303, a novel mitochondria pore modulator. TRO40303 could become the first treatment to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen post myocardial infarction (MI). The fi more

Publications AMI

• Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein: evidence in patients with acute myocardial infarction

  Publication date: Available online 9 May 2013 Source:European Journal of Pharmaceutical Sciences Author(s): Beatriz Paradela-Dobarro , Sergio Raposeiras-Roubín , Bruno K. Rodiño-Janeiro , Lilian Grigorian-Shamagian , José M. García-Acuña , Pablo Aguiar-Souto , Michel Jacquet-Hervet , Ma more

• Apamin‐Sensitive Calcium‐Activated Potassium Currents in Rabbit Ventricles with Chronic Myocardial Infarction

  Abstract Introduction Apamin‐sensitive small‐conductance calcium‐activated potassium current (IKAS) is increased in heart failure. It is unknown if myocardial infarction (MI) is also associated with an increase of IKAS. Methods and Results We performed Langendorff perfusion and optical more

• Comparing radial with femoral artery access in patients with ST-segment elevation myocardial infarction: the benefits and risks

  Expert Review of Cardiovascular Therapy , May 2013, Vol. 11, No. 5, Pages 525-527. more

Market studies AMI

• Post-Myocardial Infarction – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Post-Myocardial Infarction - Pipeline Review, H1 2012', provides an overview of the Post-Myocardial Infarction therapeutic pipeline. This report provides information on the therapeutic development for Post-Myocardial Infarction, complete with latest updates, more

• Myocardial Infarction Global Clinical Trials Review, H1, 2012

  Introduction GlobalData's clinical trial report, “Myocardial Infarction Global Clinical Trials Review, H2, 2011" provides data on the Myocardial Infarction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Myocardial Infarction. It inclu more

• Myocardial Infarction – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Myocardial Infarction - Pipeline Review, H2 2012', provides an overview of the Myocardial Infarction therapeutic pipeline. This report provides information on the therapeutic development for Myocardial Infarction, complete with latest updates, and special fea more

Websites AMI